Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupTumor, regardless of entityUrologic OncologyDiseaseRenal Cell CarcinomaTumor, Various OrgansSubgroupsarcomatoidICD10C64MeSHCarcinoma, Renal CellKidney NeoplasmsNeoplasmsSequenceCheckMate 214: NIVO3/IPIL1, RCC (PID1138) -|- NIVO240, maint. (PID1139)CheckMate 214: NIVO3/IPIL1, RCC (PID1138) -|- NIVO480, maint. (PID2260)COSMIC-313: NIVO3/IPIL1/CABO40, RCC (PID2352) -|- NIVO480/CABO40, RCC, maint. (PID2353)RCC_HCRN GU16-260: Nivolumab and Salvage Nivolumab / IpilimumabChemotherapyChemo-substanceAtezolizumabAvelumabAxitinibBevacizumabCabozantinibDoxorubicinErlotinibEverolimusGemcitabineInterferon alpha-2aIpilimumabLenvatinibNivolumabPazopanibPembrolizumabSorafenibSunitinibTemsirolimusTivozanibChemo-substanceAtezolizumabAvelumabAxitinibBevacizumabCabozantinibDoxorubicinErlotinibEverolimusGemcitabineInterferon alpha-2aIpilimumabLenvatinibNivolumabPazopanibPembrolizumabSorafenibSunitinibTemsirolimusTivozanibChemo-substanceAtezolizumabAvelumabAxitinibBevacizumabCabozantinibDoxorubicinErlotinibEverolimusGemcitabineInterferon alpha-2aIpilimumabLenvatinibNivolumabPazopanibPembrolizumabSorafenibSunitinibTemsirolimusTivozanibChemo-substanceAtezolizumabAvelumabAxitinibBevacizumabCabozantinibDoxorubicinErlotinibEverolimusGemcitabineInterferon alpha-2aIpilimumabLenvatinibNivolumabPazopanibPembrolizumabSorafenibSunitinibTemsirolimusTivozanibNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronHydrocortisoneMinocyclineParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronHydrocortisoneMinocyclineParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronHydrocortisoneMinocyclineParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronHydrocortisoneMinocyclineParacetamolPegfilgrastimNo. Substances1234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseMaintenanceSalvageTherapy intentioncurativepalliativeRisksAdrenal InsufficiencyAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaBleedingCardiotoxicityColitisConstipationDiarrheaDysphoniaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeHeadacheHemorrhageHepatotoxicityHyperglycemiaHyperkalemiaHypertensionHyperthyroidismHypertriglyceridemiaHypoalbuminemiaHypoglycemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypotensionHypothyroidismIncrease AminotransferasesIncrease in lipaseInfectionsMucositisMyocarditisMyositisNauseaNeutropeniaOral MucositisPainPancreatitisPneumonitisProteinuriaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorAtkins MB Choueiri TChoueiri TKEscudier BHaas NHudes GMotzer RMotzer RJPal SKRavaud ARini BRini B / Hutson ERini BISrinivasan RTaylor MHDiseasefortgeschrittenes, klarzelliges Nierenzellkarzinom, Erstlinie, Karnofsky > 70fortgeschrittenes, unbehandeltes Nierenzellkarzinom, klarzellig, ECOG 0-1fortgeschrittenes, unbehandeltes Nierenzellkarzinom, klarzellig, sarcomatoid, PD-L1 Expression gleich/über 1%, ECOG 0-1fortgeschrittenes, wiedergekehrtes oder metastasiertes Nierenzellkarzinom mit schlechter Prognose, Erstlinie, Karnofsky Status > 60fortgeschrittenese oder metastasiertes Nierenzellkarzinom, klarzellig, Zweitlinie nach VEGFR-Therapie, ECOG 0-1fortgeschrittenes Nierenzellkarzinom, sarkomatoid, Erstlinie, ECOG 0-1fortgeschrittenes oder metastasiertes, klarzelliges Nierenzellkarzinom, Zweitlinie, ECOG 0-2fortgeschrittenes oder metastasiertes, klarzelliges Nierenzellkarzinom, Zweitlinie, intermediäres oder niedriges Risiko, ECOG 0-2fortgeschrittenes oder metastasiertes Nierenzellkarzinom, 2.-3. Linie, Karnofsky Status > 70fortgeschrittenes oder metastasiertes Nierenzellkarzinom, ECOG 0-1fortgeschrittenes oder metastasiertes Nierenzellkarzinom, Erstliniefortgeschrittenes oder metastasiertes Nierenzellkarzinom, Erstlinie, Karnofsky Status >70fortgeschrittenes oder metastasiertes Nierenzellkarzinom, klarzellig, ErstlinieHLRCC-assoziiertes oder sporadisches papilläres Nierenzellkarzinom, ECOG 0-2Klarzelliges Nierenzellkarzinom, metastasiert oder lokal fortgeschritten, Erstlinie, ECOG 0-2locoregionales Nierenzellkarzinom nach Nephrektomie, Hochrisiko: Tumorstadium > 3 und/oder regionale Lymphknotenmetastasen, Erstlinie, ECOG 0-2lokal fortgeschrittener oder metastasierter Tumor, unabhängig von der Entität, progredient nach 2 oder weniger Therapielinien, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Nierenzellkarzinom mit einer klarzelligen Komponente, Intermediate-/poor-risk nach IMDCmetastasiertes, klarzelliges Nierenzellkarzinom, ECOG 0-1metastasiertes, klarzelliges Nierenzellkarzinom, Erstlinie, ECOG 0-1metastasiertes Nierennzellkarzinom, klarzellig, Zweitlinie, Karnofsky Status > 70%metastasiertes Nierenzellkarzinom, Resektion oder partielle Resektion, Erstlinie, Karnofsky Status >70%neu diagnostiziertes oder rezidiviertes Nierenzellkarzinom, Stadium IV, Erstlinie, Karnofsky > 70Patienten mit Nierenzellkarzinom in der Zweitlinie / Erstlinie, klarzellig, ECOG 0-1R0 reseziertes klarzelliges Nierenzellkarzinom, hohes Rezidivrisiko, adjuvant, +/- MetastasektomieOriginAbramson Cancer Center, Philadelphia, ECOG 8802Checkmate 025 StudieCity of Hope Comprehensive Cancer Center, Duarte, USA, COSMIC-021 StudyCleveland Clinic Taussig Cancer, KEYNOTE-426 InvestigatorsCleveland Clinig Taussig Cancer Institute, Main Campus, Cleveland, Ohio, AXIS trial / Baylor Sammons Cancer Center, Dallas TexasDana-Farber Cancer Institute, Boston, KEYNOTE-564Dana-Farber Cancer Institute, Boston, METEOR investigatorsDana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, USA, CheckMate 9ER trialDepartment of Medical Oncology, Hôpital Saint André, Bordeaux, S-TRAC trialFox Chase Cancer Center, PhiladelphiaGeorgetown Lombardi Comprehensive Cancer Center, Washington, HCRN GU16-260 trialInstitut Gustave Roussy, Villejuif, France, AVOREN trialInstitut Gustave Roussy, Villejuif, France, TARGET study groupKnight Cancer Institute, Oregon Health and Science University, Portland, USALank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, COSMIC-313 trialMemorial Sloan-Kettering Cancer Center, Kimmel Center, New YorkMemorial Sloan-Kettering Cancer Center, New YorkMemorial Sloan-Kettering Cancer Center, New York, HOPE 205Memorial Sloan-Kettering Cancer Center, NY, (COMPARZ)Memorial Sloan Kettering Cancer Center, 1275 York Ave., New YorkMemorial Sloan Kettering Cancer Center, Memorial Hospital, New York, CheckMate 214Memorial Sloan Kettering Cancer Center, New York, CLEAR trial, KEYNOTE-581Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA, IMmotion151Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, BethesdaProtocols in Revision 32 protocols foundAtezolizumab 1200 / Bevacizumab 15, Renal Cell Carcinoma (PID1604 V1.0)Atezolizumab 1200 / Cabozantinib 40, Renal Cell Carcinoma (PID1957 V1.1)Avelumab 800 / Axitinib 5, Renal Cell Carcinoma (PID1353 V2.3)Axitinib 5, Renal Cell Carcinoma (PID737 V1.2)Bevacizumab 10 / Interferon Alpha-2a 9 M, Renal Cell Carcinoma (PID788 V1.0)Cabozantinib 60, Renal Cell Carcinoma (PID736 V1.2)Doxorubicin 50 / Gemcitabine 1500, Renal Cell Carcinoma (PID1979 V1.0)Erlotinib 150 / Bevacizumab 10, Renal Cell Carcinoma (PID2975 V1.0)Everolimus 10, Renal Cell Carcinoma, second-line (PID731 V1.0)Lenvatinib 18 / Everolimus 5, Renal Cell Carcinoma, second line (PID850 V1.0)Lenvatinib 20 / Pembrolizumab 200, Renal Cell Carcinoma (PID1927 V1.0)Lenvatinib 20 / Pembrolizumab 200, Tumor, Various Organs (PID1518 V1.0)Nivolumab 240 / Cabozantinib 40, Renal Cell Carcinoma (PID1730 V1.2)Nivolumab 240, Renal Cell Carcinoma, second-line (PID729 V2.0)Nivolumab 240, Renal Cell Carcinoma, cycle 1-6 (PID2156 V1.0)Nivolumab 3 / Ipilimumab 1 - Nivolumab 240, Renal Cell Carcinoma, maintenance (PID1139 V1.1)Nivolumab 3 / Ipilimumab 1 - Nivolumab 480, Renal Cell Carcinoma, maintenance (PID2260 V1.0)Nivolumab 3 / Ipilimumab 1 / Cabozantinib 40, Renal Cell Carcinoma (PID2352 V1.1)Nivolumab 3 / Ipilimumab 1, Renal Cell Carcinoma (PID1138 V1.2)Nivolumab 3 / Ipilimumab 1, Renal Cell Carcinoma, salvage (PID2159 V1.1)Nivolumab 360, Renal Cell Carcinoma, Cycle 7-10 (PID2157 V1.0)Nivolumab 480 / Cabozantinib 40, Renal Cell Carcinoma, maintenance (PID2353 V1.1)Nivolumab 480, Renal Cell Carcinoma, Second Line (PID1135 V1.0)Nivolumab 480, Renal Cell Carcinoma, cycle 11+ (PID2158 V1.0)Pazopanib 800, renal cell carcinoma (PID94 V1.0)Pembrolizumab 200 / Axitinib 5, Renal Cell Carcinoma (PID1219 V1.1)Pembrolizumab 200, Renal Cell Carcinoma, adjuvant (PID1834 V1.0)Sorafenib 400, Renal Cell Carcinoma (PID743 V1.1)Sunitinib 50, Renal Cell Carcinoma (PID730 V1.0)Sunitinib 50, Renal Cell Carcinoma, adjuvant (PID803 V1.0)Temsirolimus 25, Renal Cell Carcinoma (PID787 V1.0)Tivozanib 1.34, Renal Cell Carcinoma (PID489 V1.0)
